Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Improving type 2 diabetes using incretin analogues is becoming increasingly plausible. Currently, tirzepatide is the most promising listed incretin analogue. Here, I briefly explain the evolution of drugs of this kind, analyze the residue discrepancies between tirzepatide and endogenous incretins, summarize some existing strategies for prolonging half-life, and present suggestions for future research, mainly involving biased functions. This review aims to present some useful information for designing a dual glucagon like peptide-1 receptor/glucose-dependent insulinotropic polypeptide receptor agonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“incretins, glucagon like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), have been identified.(1) GLP-1 receptor agonists are broadly applied in type 2 diabetes mellitus (T2DM) therapy.”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 10×
“the second residue of exenatide is Gly rather than Ala; thus, it can circumvent the degradation of dipeptidyl peptidase-4 (DPP-4) and has a prolonged intravenous half-life of 30 min and a 2–3 h half-life after subcutaneous administration.(2) Liraglutide is designed to bind to human albumin via a C16 fatty acid and a s…”
InfluentialCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 15×
“The mechanism remains unclear; Moon et al suggested a hypothesis that GLP-1 Thr 13 interacts with a binding pocket formed by Ile 196 , Leu 232 , and Met 233 of GLP-1R because Thr 7 -containing chimeric peptides are highly sensitive for the Ile 196 mutation; 24 but it contradicts the model constructed by Zhang et al th…”
InfluentialFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1×
“The dose of 5mg MAR709 was determined to be not tolerated(54) while a wide dose range of tirzepatide from 1mg to 15mg was established.(52) The discrepancy of clinical efficacy of these two drugs is due at least partially to their difference of proportion of GLP-1 and GIP activity.”
BackgroundKnudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 2×
“15,23 Tyr 1 and Ile 7 are crucial for the selective activation of GIPR by GIP.”
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein
Zhang, Y., Sun, B., Feng, D., Hu, H., Chu, M., Qu, Q., Tarrasch, J. T., Li, S., Sun Kobilka, T., Kobilka, B. K., et al. (2017) · Nature · doi:10.1038/nature22394 · Cited by 576
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 2×
“56 This may be the secret of the extraordinary efficacy of tirzepatide, but it is still possible that the best ratio of GLP-1 and GIP activity in a dual agonist has not been discovered.”
Cited by
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials
Popoviciu, M.-S., Păduraru, L., Yahya, G., Metwally, K., & Cavalu, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310449 · Cited by 280
“moiety through a spacer in order to bind albumin and hence diminish renal clearance [50] (Figure 8).”
BackgroundIncretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review
Chavda, V. P., Ajabiya, J., Teli, D., Bojarska, J., & Apostolopoulos, V. (2022) · Molecules · doi:10.3390/molecules27134315 · Cited by 208
Natural products and drug discovery
Newman, D. J. (2022) · National Science Review · doi:10.1093/nsr/nwac206 · Cited by 169
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0277 · Cited by 131
Therapeutic horizons in metabolic dysfunction–associated steatohepatitis
Newsome, P. N., & Loomba, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186425 · Cited by 90
Taktaz, F., Fontanella, R. A., Scisciola, L., Pesapane, A., Basilicata, M. G., Ghosh, P., Franzese, M., Tortorella, G., Puocci, A., Vietri, M. T., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02319-7 · Cited by 72
Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214334 · Cited by 66
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Corrao, S., Pollicino, C., Maggio, D., Torres, A., & Argano, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1402583 · Cited by 62
The signaling pathways in obesity‐related complications
Chandrasekaran, P., & Weiskirchen, R. (2024) · Journal of Cell Communication and Signaling · doi:10.1002/ccs3.12039 · Cited by 55
The promise of tirzepatide: A narrative review of metabolic benefits
Sokary, S., & Bawadi, H. A. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.03.008 · Cited by 44
Polypharmacology: new drugs in 2023–2024
Ryszkiewicz, P., Malinowska, B., & Schlicker, E. (2025) · Pharmacological Reports · doi:10.1007/s43440-025-00715-8 · Cited by 45
Jensen, T. L., Brønden, A., Karstoft, K., Sonne, D. P., & Christensen, M. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s419304 · Cited by 36
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Chrysavgis, L., Kazanas, S., Bafa, K., Rozani, S., Koloutsou, M. E., & Cholongitas, Ε. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073832 · Cited by 26
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
Rohani, P., Malekpour Alamdari, N., Bagheri, S. E., Hekmatdoost, A., & Sohouli, M. H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1230206 · Cited by 18
Liarakos, A. L., & Koliaki, C. C. (2023) · Biomedicines · doi:10.3390/biomedicines11071875 · Cited by 16
Newman, D. J. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00886 · Cited by 14
Alenezi, B. T., Elfezzani, N., Uddin, R., Patel, H., Chester, S., Abdelmaksoud, A., Hussein, M. H., Zaitone, S. A., Fawzy, M. S., Aiash, H., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164896 · Cited by 13
Tirzepatide a novel anti diabetic molecule unfold dual action
Sweta, Gupta, S., Bansal, S., Devi, S., Sharma, S., Laxmi, L., & Deepa (2024) · Discover Public Health · doi:10.1186/s12982-024-00200-2 · Cited by 14
Recent advances, strategies, and future perspectives of peptide-based drugs in clinical applications
Yang, Q., Hu, Z., Jiang, H., Wang, J., Han, H., Shi, W., & Qian, H. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60800-4 · Cited by 20
Biased agonism in peptide-GPCRs: A structural perspective
Jayakody, T., Budagoda, D. K., Mendis, K., Dilshan, W. D., Bethmage, D., Dissasekara, R., & Dawe, G. S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108806 · Cited by 11
Chen, N., Zhang, M., Shi, B., Luo, X., Huang, R., Luo, Z., He, J., Xue, S., Li, N., Ling, Z., et al. (2025) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2025.09.002 · Cited by 12
Relationship between hepatic lipid accumulation and type 2 diabetes mellitus
Wang, Z., Zan, W., Fan, Z., & Wang, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118723 · Cited by 8
The role of glucagon-like peptides in osteosarcopenia
Tufail, E., Sanyal, S., Mithal, A., Sanyal, S., & Chattopadhyay, N. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0210 · Cited by 12
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
Chen, H., Ding, Y., & Shan, Y. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468860 · Cited by 12
Zou, X., He, Y., Gao, Y., Wang, J., & Zhang, J. Z. H. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146141 · Cited by 6
Petsas, E., Kiouri, D. P., Georgiou, N., Siasos, G., Mavromoustakos, T., & Chasapis, C. T. (2025) · Molecules · doi:10.3390/molecules30214240 · Cited by 9
A Survey and Guide to the Development of Fatty Acid‐derivatized Peptide Therapeutics
Jacobsen, M. T., Poulsen, C., Kopp, K. L., Olsen, J., & Cox, N. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch07 · Cited by 5
Elangovan, H., Loomba, R. S., Muthiah, M. D., Schattenberg, J. M., Zheng, M., Noureddin, M., Mantzoros, C. S., & George, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0857 · Cited by 4
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Tirzepatide – a new analogue of incretin hormones
Anglart, G., Janik, L., & Dettlaff, K. (2023) · Farmacja Polska · doi:10.32383/farmpol/174068 · Cited by 3
Pharmacotherapy in obesity: the current state and the near future
Cho, Y. J., & Kim, K. K. (2022) · Journal of Korean Medical Association · doi:10.5124/jkma.2022.65.8.514 · Cited by 3
Low Molecular-Mass Hormones: Peptidic and Steroidal Hormones
Gelves, L. G. V., Trindade, A. C. L. B., & Lima, L. M. (2024) · Topics in medicinal chemistry · doi:10.1007/7355_2024_176 · Cited by 2
Kettős inkretinterápia – új lehetőség a 2-es típusú diabetes vércukorcsökkentő kezelésében
Winkler, G., Kis, J. T., & Schandl, L. (2022) · Lege Artis Medicinae · doi:10.33616/lam.32.019 · Cited by 4
Piťhová, P. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.009 · Cited by 1
Efficacy and Safety of Tirzepatide in the Treatment of Obesity in Adults: A Comprehensive Review
Skonieczna, K., Wiciun, O., Ordon, K., Badziąg, M., Szulc, P., Kurczoba, L., Kłossowska, M., & Kądziołka, O. (2025) · Quality in Sport · doi:10.12775/qs.2025.41.60368 · Cited by 1
Fu, L., Fan, J., Zhong, J., Xie, X., Yang, S., & Yue, X. (2026) · Clinical Medicine Frontiers · doi:10.57237/j.cmf.2026.01.001 · Cited by 1
Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
Dong, S., Xu, Y., Gan, R., Zhang, A., He, J., & Tang, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70049 · Cited by 1
Brož, J., Koželuhová, M., Michalec, J., & Lukáč, O. (2026) · Česká a slovenská farmacie · doi:10.36290/csf.2026.020 · Cited by 1
Liu, Y., & Liu, X. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119717 · Cited by 1
Diabetes Mellitus and Natural Product‐based Drug Discovery
Newman, D. J. (2023) · Wiley eBooks · doi:10.1002/9781119983347.ch1 · Cited by 1
Xia, X., Lin, Q., Zhou, Z. M., & Chen, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109377 · Cited by 2
The glucagon-like peptide-1 (GLP-1) drugs poised to conquer obesity
Yin, J., Liu, Y., & Jia, W. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0417
Mariam, Z., Abolhassan, M. R., Reynolds, C. A., Yousefi, R., & Deganutti, G. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152525
TARGETING MULTIPLE PATHWAYS WITH ONE MOLECULE: THE THERAPEUTIC VERSATILITY OF TIRZEPATIDE
Jędrzejewska-Rzezak, P., Żuczek, A., Dyndał, K., Broda, M., Żuczek, O., Urbańska, K., Szczap, I., Hawryluk, A., Marzec, K., & Mokrzycka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3902
Al-Sammak, U. (2023) · DiVA at Umeå University (Umeå University) · Cited by 1
Karagiannidis, A. G. (2023) · University of Thessaly Institutional Repository (University of Thessaly) · doi:10.26253/heal.uth.39000
TIRZEPATIDE - A NEW ERA IN OBESITY TREATMENT? A REVIEW OF THE CURRENT STATE OF KNOWLEDGE
Solarz, A., Kryślak, J., Szabelski, S., Graczyk, E., Sokołowski, M., & Oskroba, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4143
Fu, L., Fan, J., Yue, X., Yang, S., Xie, X., & Zhong, J. (2026) · Medical Research Frontiers · doi:10.57237/j.mrf.2025.04.001
Iwona, K., Gawalska, A., Kasprzycka, P., Stępniewski, M., Rózga, P., Pałka, A., Shubin, A., Bukato, K., Galazka, M., Burchard, E., et al. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md01086a
Lechi, F., Khalil, A., Bautista, P. N., Öberg, J., Balestri, L. J. I., Eriksson, O., Eriksson, J., & Odell, L. R. (2026) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-026-00486-4
Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity
Palmer, M. (2026) · Clinical Therapeutics · doi:10.1016/j.clinthera.2026.09.002
PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide
Tudi, K., Jie, Z., Chen, Z., Liao, W., Liu, Y., & Tang, G. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00761
BindingDB Entry 50022803: Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
BindingDB (2026) · UC San Diego · doi:10.7270/q2028xcf
Sanville, M., Dambra, R., Werth, E., Oquendo, E., Herrmann, M., & Saini, G. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01311-1
Metadata
- Authors
- Wang, L.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- Wang, Lijing
- ORCID
- Wang, Lijing
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-05
- Volume
- Volume 16
- Pages
- 1547-1559
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC9149770
- OpenAlex
- W4281388633
- Cited by
- 56
- References
- 67
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 15 · 2023: 8 · 2022: 4
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- tirzepatide, GIP/GLP-1 receptor agonist, GLP-1 receptor, GIP receptor, incretin analogues, type 2 diabetes, biased agonism, drug half-life extension, drug design
- MeSH terms
- Tirzepatide, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Receptors, Gastrointestinal Hormone, Receptors, G-Protein-Coupled, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.